In our study, most of the patients were female, with almost half of them between 20–39 years. The age at presentation of breast cancer in West African women is between 35–45 years, unlike Caucasians who present in the fifth and sixth decade (8, 9, 17). Sierra Leone like other West African countries is made of younger population with over 80% under 35 years of age, which accounts for the high number of young women presenting with breast cancer with few old patients living into their 5th or 6th decades (17–21). About 62.9% of patients, were married and 37.7% were involved in some form of trading activity for their main source of income. The left was the most commonly affected breast (n = 130, 51.2%) and bilateral breast cancer was reported in 2% of patients (22–24).
Late presentation with advanced disease was common among patients in this study with Stage III B accounting for nearly half of the cases at presentation (22, 24). Though Shepherd (2004) reported that 96.9% of women in Sierra Leone had some knowledge of breast cancer and were aware that early presentation is key for improved clinical outcome, yet most patients with breast cancer presented with locally advanced disease at our clinic. Similar findings were reported in studies conducted in tertiary health facilities in Nigeria and Ghana where despite a low incidence of breast cancer in these countries, high number of patients presented with advanced disease (7, 22, 25). Ignorance of the disease symptoms, lack of access to quality care and lack of trust of western medicine (9, 26), fear of diagnosis (19) and lack of access to screening services (17, 22) have been found to be among the causes of late presentation of breast cancer patients in Africa. In a previous study conducted in Sierra Leone and Rwanda, Ntirenganya (2014) identified 3.3% of women with breast masses during a community surveillance study. Poor recognition of symptoms and reliance on traditional healers were the barriers identified that prevented women from accessing healthcare services when they felt a mass in their breasts (12).
About 2% of patients in this study presented with bilateral breast cancer and 13.8% presented with metastatic disease at presentation. Pulmonary metastasis was the most common site followed by the skin, liver and the other breast unlike other studies (23, 27). The brain and bone accounted for the least site of metastasis seen at presentation. De novo presentation with metastasis is reported amongst breast cancer patients, with incidence of 14–25% in Asian patients, (23, 28) 3–6% in European patients (29) and 14% in sub-Saharan Africa (22). The aggressive nature of breast cancer is reported amongst black patients with high incidence of triple negative disease (30, 31), high mitotic rate (32), increased tumour size, high grade, positive axillary lymph node status (30) and distinct mutations in BRAC 1 and BRAC 2 (33). The lack of resources in-country, made it difficult to do similar genomic analytic profiling of the breast cancers in Sierra Leone, which make it difficult for evidence-based management of cases.
Breast cancer treatment is multimodal with surgery, chemotherapy, radiotherapy and immunotherapy depending on the tumour histology and stage of the disease at presentation. In our study, almost half of the patients had mastectomy and it was the most common treatment offered. It is also the main modality of treatment in health institutions where patients present mostly with locally advanced disease (7, 23). Mastectomy remains the main modality of treatment for breast cancer patients in Africa (17, 34). This has been attributed to unavailability of adjuvant therapy such as radiotherapy and chemotherapy (9, 34). The proportion of mastectomy in this study was lower than that reported in the sub-region (7). Limited number of breast surgeons, patients concern about removal of their breast for cosmetic reasons, cultural and spiritual beliefs are some of the reasons reported regarding patients refusing mastectomy for breast cancer treatment in sub-Saharan Africa (35, 36). Mastectomy as a treatment option was a major concern of many of our patients and could account for the loss to follow up of some of them after their first visit to the clinic. Advanced stage at presentation and unavailability of radiotherapy services makes breast conserving surgery not a feasible option for many patients in Sierra Leone, and other countries in the sub-region (34). Radiotherapy services are currently not available in Sierra Leone and patients who require it have to travel to neighbouring countries such as Ghana, Nigeria or Senegal. Radiotherapy services is a major challenge in many African countries and amongst those with radiotherapy machines, frequent breakdown is a common problem often reported (16, 19).
About a third of our patients received neoadjuvant and adjuvant chemotherapy drugs. Though the anthracyclines are in the essential medicine list in Sierra Leone, yet they are scarcely available and few pharmacies in the capital city stock them or are willing to procure them for patients. High cost, unavailability of some chemotherapy drugs and drug toxicities are major factor limiting drug compliance for breast cancer patients (16, 19).
Immunohistochemistry services is currently not available in the country and specimens are usually flown to South Africa, Ghana or Nigeria for further analysis. Immunotherapy drugs like Herceptin is also not available in Sierra Leone and patients who can afford it procure it abroad. Similar findings were reported in a study reviewing breast cancer facilities in sub-Saharan countries (16, 19).
Patients are placed on hormonal therapy with Tamoxifen and aromatase inhibitors such as Anastrozole post mastectomy and as adjuvant treatment in some cases of inoperable tumours. Hormonal therapy is accessible and affordable especially Tamoxifen. Their use is advocated in low resource settings as they are inexpensive with tolerable side effect (18). It is expected that with improvement of pathology services in the hospital, receptor status and immunohistochemistry services will be available locally and will guide and improve the use of hormonal treatment in our practice. Palliative care plays a key role in patients’ management in our setting as most present with advanced or metastatic disease. Inpatient and outpatient palliative care services are available for patients with breast cancer and other malignancies at the Connaught hospital.
Our study shows a gradual increase in the number of patients managed with breast cancer over the four-year period under review at the Connaught hospital. The incidence of breast cancer continues to rise in Sierra Leone as in many sub-Saharan countries (34), with an overall increase in the mortality from the disease. The mortality recorded during the four-year period was 21.7%. Similar results were obtained in studies conducted in other tertiary health facilities in Nigeria and Uganda, 23.3% and 23% respectively (19, 37). Though there has been an increase in the number of breast cancer patients managed over the years, yet 15.2% were lost to follow up and did not initiate any form of treatment. Cost of care associated with chemotherapy and fear of losing their breast may account for the loss to follow-up of these patients. Mastectomy is not acceptable to many patients in sub-Saharan Africa (38, 39). In our study, calls to relatives of patients lost to follow-up revealed that most admitted to seeking traditional or spiritual care and confirmed their relatives were now dead. In Sokoto, Nigeria, high cost of care and presumed death of patients were possible causes for loss of follow-up of breast cancer patients managed in a tertiary health facility (7). The number of patients in remission has increased over the years as more patients are now reporting and being managed for the disease. A prospective study will provide more details about the long-term survival outcome of our patients.